MX2020008195A - Compuestos para el tratamiento del dolor. - Google Patents

Compuestos para el tratamiento del dolor.

Info

Publication number
MX2020008195A
MX2020008195A MX2020008195A MX2020008195A MX2020008195A MX 2020008195 A MX2020008195 A MX 2020008195A MX 2020008195 A MX2020008195 A MX 2020008195A MX 2020008195 A MX2020008195 A MX 2020008195A MX 2020008195 A MX2020008195 A MX 2020008195A
Authority
MX
Mexico
Prior art keywords
pain
compounds
treatment
useful
subject
Prior art date
Application number
MX2020008195A
Other languages
English (en)
Inventor
Markus Haeberlein
Thomas Andrew Wynn
Juan C Alvarez
Demetri Theodore Moustakas
Lewis D Pennington
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of MX2020008195A publication Critical patent/MX2020008195A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Abstract

En la presente se proporcionan compuestos que son útiles en el tratamiento del dolor en un sujeto.
MX2020008195A 2018-02-05 2019-02-04 Compuestos para el tratamiento del dolor. MX2020008195A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862626499P 2018-02-05 2018-02-05
PCT/US2019/016543 WO2019152946A1 (en) 2018-02-05 2019-02-04 Compounds for the treatment of pain

Publications (1)

Publication Number Publication Date
MX2020008195A true MX2020008195A (es) 2020-11-24

Family

ID=65444375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008195A MX2020008195A (es) 2018-02-05 2019-02-04 Compuestos para el tratamiento del dolor.

Country Status (14)

Country Link
US (3) US10604489B2 (es)
EP (1) EP3749667A1 (es)
JP (1) JP2021512952A (es)
KR (1) KR20200136384A (es)
CN (1) CN111989327A (es)
AU (1) AU2019216522A1 (es)
BR (1) BR112020015712A2 (es)
CA (1) CA3090385A1 (es)
EA (1) EA202091881A1 (es)
IL (1) IL276482A (es)
MA (1) MA51738A (es)
MX (1) MX2020008195A (es)
SG (1) SG11202007422QA (es)
WO (1) WO2019152946A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200136384A (ko) * 2018-02-05 2020-12-07 알케르메스, 인코포레이티드 통증 치료용 화합물
WO2021026377A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Lactam-containing compounds for the treatment of pain
WO2021026378A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Indole compounds for the treatment of pain
WO2021026380A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Phenyltriazole compounds for the treatment of pain
WO2021026375A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Fused bicyclic compounds for the treatment of pain
TW202142537A (zh) 2020-02-04 2021-11-16 美商艾爾凱默斯公司 ３－（（１Ｒ，５Ｓ，９ｒ）－９－乙氧基－３－氮雜雙環并［３．３．１］壬烷－９－基）—苯甲醯胺之結晶形式及其鹽形式

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3167562A (en) 1965-01-26 New j-azabicyclo
GB952137A (en) 1961-03-14 1964-03-11 Sankyo Co New 3-azabicyclo [3.3.1] nonane compounds and a process for preparing these compounds
US3196154A (en) 1962-05-17 1965-07-20 Sterling Drug Inc 3-substituted-9-methyl-3, 9-diazabicyclo [3.3.1] nonanes
US3475439A (en) 1966-05-07 1969-10-28 Sankyo Co 3-azabicyclo(3.3.1)nonane compounds
GB1195746A (en) 1967-06-07 1970-06-24 Yoshitomi Pharmaceutical 3-Azabicyclo [3,3,1] Nonane Derivatives
GB1393253A (en) 1971-09-10 1975-05-07 Wyeth John & Brother Ltd 3-azabicyclo-3,3,1-nonanes
JPS4856680A (es) 1971-11-18 1973-08-09
JPS4961168A (es) 1972-10-14 1974-06-13
IL59004A0 (en) * 1978-12-30 1980-03-31 Beecham Group Ltd Substituted benzamides their preparation and pharmaceutical compositions containing them
WO1991018901A1 (fr) 1990-06-05 1991-12-12 Toray Industries, Inc. Derives d'indole
EP0483403A1 (en) 1990-10-31 1992-05-06 Hoechst Aktiengesellschaft Derivatives of amino acids as inhibitors of renin, methods for their preparation, medicaments containing them and their use
DE4341403A1 (de) 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
US5541217A (en) 1995-05-17 1996-07-30 Ortho Pharmaceutical Corporation 4-arylcyclopenta[c]pyrrole analgesics
JP2808089B2 (ja) 1995-08-29 1998-10-08 レーザーテクノ株式会社 墨出し用レーザー装置
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
DE19952146A1 (de) 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU2003210730A1 (en) * 2002-02-15 2003-09-09 Pharmacia And Upjohn Company Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
EP1615894A2 (en) 2003-04-14 2006-01-18 Pfizer Products Inc. 3-azabicyclo 3.2.1 octane derivatives
US7056930B2 (en) 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
PL1678172T3 (pl) 2003-10-15 2010-05-31 Targacept Inc Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego
CN101005838A (zh) 2004-06-22 2007-07-25 先灵公司 ***素受体配体
WO2007029156A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Isoindoledione derivatives as adrenergic receptor antagonists
US7538110B2 (en) 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
US7488726B2 (en) 2005-11-03 2009-02-10 Activbiotics Pharma, Llc Rifamycin analogs and uses thereof
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
TWI423801B (zh) 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
US8048895B2 (en) 2008-04-18 2011-11-01 Research Triangle Institute Kappa opioid receptor ligands
GB0815947D0 (en) 2008-09-02 2008-10-08 Univ Dundee Compounds
EP2485735B1 (en) 2009-10-08 2015-07-29 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (fabp)
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
JP5713367B2 (ja) 2010-06-04 2015-05-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体
WO2012075232A1 (en) 2010-12-04 2012-06-07 Trevena, Inc. Opioid receptor ligands and methods of using and making the same
CN103702561B (zh) 2011-03-23 2017-02-22 特维娜有限公司 阿片样物质受体配体以及使用和制备其的方法
JP2014237589A (ja) 2011-09-28 2014-12-18 日本曹達株式会社 環状アミン化合物および有害生物防除剤
GB2498976A (en) 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
JP2015083543A (ja) 2012-02-14 2015-04-30 大日本住友製薬株式会社 新規縮環ピロリジン誘導体
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug
WO2015091931A1 (en) 2013-12-20 2015-06-25 AbbVie Deutschland GmbH & Co. KG Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases
NO2721710T3 (es) 2014-08-21 2018-03-31
EP3506983B1 (en) 2016-09-01 2021-08-25 Mebias Discovery, Inc. Substituted urea-derivatives for the treatment of pain
WO2018136546A1 (en) 2017-01-17 2018-07-26 Mebias Discovery Llc Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same
KR20200136384A (ko) * 2018-02-05 2020-12-07 알케르메스, 인코포레이티드 통증 치료용 화합물

Also Published As

Publication number Publication date
US20200255383A1 (en) 2020-08-13
US10604489B2 (en) 2020-03-31
EA202091881A1 (ru) 2020-11-10
IL276482A (en) 2020-09-30
EP3749667A1 (en) 2020-12-16
JP2021512952A (ja) 2021-05-20
WO2019152946A1 (en) 2019-08-08
MA51738A (fr) 2021-05-12
US20190241524A1 (en) 2019-08-08
CA3090385A1 (en) 2019-08-08
AU2019216522A1 (en) 2020-08-27
US11180455B2 (en) 2021-11-23
KR20200136384A (ko) 2020-12-07
US20220033394A1 (en) 2022-02-03
BR112020015712A2 (pt) 2020-12-08
CN111989327A (zh) 2020-11-24
SG11202007422QA (en) 2020-09-29

Similar Documents

Publication Publication Date Title
CA193736S (en) Skin massager
MX2020008195A (es) Compuestos para el tratamiento del dolor.
GB2541571A (en) Pharmaceutical compositions
IL276398A (en) Combined treatment for mastocytosis
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
TN2019000211A1 (en) Antitumoral compounds
GB201813876D0 (en) Treatment
IL288937A (en) Improved treatment using eyp001
IL281792A (en) Treatment methods
GB201800546D0 (en) Treatment
IL281997A (en) Combined treatment for the treatment of uveal melanoma
IL281839A (en) Treatment methods
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MX2020003575A (es) Nuevos derivados de alcoxiamino para tratar dolor y estados relacionados con dolor.
GB201914296D0 (en) Treatment
CA187131S (en) Casket
SG11202101196TA (en) Behavioural treatment
GB201814905D0 (en) Treatment
GB201912760D0 (en) Treatment
GB201912335D0 (en) Treatment
GB201912365D0 (en) Treatment
GB201911816D0 (en) Treatment
GB201911603D0 (en) Treatment